Amanda E N Jojo

The National Biotechnology Authority in partnership with Chengie Research and Gulf Pharmaceuticals Zimbabwe has developed an innovative cough syrup, COFSOL.

The syrup is composed of Zimbabwe’s naturally occurring herb, Zumbabni, Lippia Javanica.

The development of COFSOL syrup coincided with the National Biotechnology Authority’s 15th anniversary and the launch of its New Strategic Plan 2021-25 which was officiated by President Emmerson Mnangagwa.

Speaking at the launch, President Mnangagwa said the development marks a notable step in the nation trajectory towards enhanced scientific research as well as innovations in the pharmaceutical industry.

“To ensure the consistent availability of the primary ingredients of the COFSOL syrup, I challenge stakeholders to venture into contract farming and the use of bio-technological innovations.

“As a nation, we will undoubtedly emerge stronger through the adaptation of our traditional and natural resources for our health and well-being,” President Mnangagwa said.

He further challenged the Authority, higher learning institutions and the private sector, Zimbabwe’s skilled human capital to utilize their scientific knowledge for advancing research and development in traditional medicines.

“The manufacturing of more products using our locally available natural endowments should be prioritized.

“The time has come for the sector to vigorously pursue and invest in the manufacturing of our own drugs and medicine,” President Mnangagwa.

The pharmaceutical sector have been implored to shift its paradigm from being mere wholesalers and retailers of drugs produced in other jurisdictions.

“The commercial potential of Zumbani and other traditional whose value addition potential is under-exploited, remains essential, the sector must explore research around many more plants and natural products occurring within our country,” President Mnangagwa said.

He urged the pharmaceutical industry to harness trade arrangements in the regional and international markets.

“I urge the industry to market its products and ensure utmost quality assurance, through adhering to good manufacturing practices and competitive business strategies,” he added.

President Mnangagwa applauded the institution for coming up with the National Biotechnology Strategy as it is aligned with economic blueprint, National Development Strategy 1.

“The implementation of the Strategy by the National Biotechnology Authority should give impetus to unlocking the full potential of bio-technology and ensure that Zimbabwe fully embraces the gains associated with the industry,” President Mnangagwa said.